We are currently completing a Phase 1b clinical trial with OMP-305B83 (navicixizumab) in combination with paclitaxel in patients with heavily pre-treated platinum-resistant ovarian cancer. Ovarian cancer remains a deadly malignancy because most patients develop recurrent disease that is resistant to chemotherapy, including platinum.

OMP-305B83 (navicixizumab) is an anti-DLL4/VEGF bispecific antibody targeting both DLL4 in the Notch cancer stem cell pathway and vascular endothelial growth factor (VEGF). This antibody is expected to have anti-angiogenic plus anti-cancer stem cell activity. In a Phase 1a clinical trial in 66 patients, OMP-305B83 (navicixizumab) demonstrated single-agent anti-tumor activity and was safe enough to be administered on a continuous basis.

Patient resources

Information on navicixizumab clinical trials is available here: Navicixizumab ClinicalTrials.gov.

Public presentations of studies on navicixizumab include:

View clinical studies

For Partnering